Biopharmx Corp (NYSEAMERICAN:BPMX) gapped down before the market opened on Wednesday . The stock had previously closed at $0.25, but opened at $0.19. Biopharmx Corp shares last traded at $0.13, with a volume of 17291400 shares.

A number of research firms have issued reports on BPMX. Maxim Group reiterated a “buy” rating and set a $1.50 target price (down from $3.00) on shares of Biopharmx Corp in a report on Wednesday, September 13th. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of Biopharmx Corp in a report on Tuesday, September 19th.

Biopharmx Corp (NYSEAMERICAN:BPMX) last posted its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.06) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%.

In other Biopharmx Corp news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the firm’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $0.20, for a total transaction of $59,278.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

WARNING: “Biopharmx Corp (BPMX) Shares Gap Down to $0.19” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/biopharmx-corp-bpmx-shares-gap-down-to-0-19/1720430.html.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.